title: [Genotypic drug-resistance of HIV-1 CRF01_AE in Zhejiang province, 2004-2007].
abstract: OBJECTIVE
  To study the genotypic drug-resistant mutation among treat-naïve or treated patients infected with HIV-1 CRF01_AE in Zhejiang province during 2004-2007.
  
  
  METHODS
  HIV-1 pol amplicons (PR + RT) from 13 treated and 43 treat-naïve patients were obtained by reverse transcription-polymerase chain reaction (RT-PCR). The sequences were analyzed for genotypic antiretroviral resistance through online tools (http://hivdb.stanford.edu).
  
  
  RESULTS
  The median count of CD4+ T lymphocytes in 43 treat-naïve patients was 229 cells /mm3 and the median log10 viral load was 3.41. Some drug-resistant mutations were seen in these samples including amino acid 10, 46, 71, in the genes ofprotease (PR) and 103, 118, in the genes of reverse transcriptase (RT) whereas twenty-nine resistance mutations in the genes of PR and RT were obtained in the 13 treated patients (8/13, 61.5%). The high prevalence of drug-resistant mutations was observed in patients who had been receiving HAART (hight active antiretroviral therapy). Among them, cross drug resistance was dominant. Correspondingly, the median counts of CD4+ T lymphocytes and the log10 viral load were 186 cells/mm3 and 3.91.
  
  
  CONCLUSIONS
  There was a low prevalence of genotypic drug-resistant mutations in treat-naïve patients, but higher drug-resistant mutation in treated patients. More attention should be paid to the transmission of drug-resistant HIV strains and the antiretroviral therapy recipe should be adjusted correspondingly for the development of ART drugs, intervention as well as clinical therapy programs.
authors.affiliation: Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China.
authors.forename: Ya-ping
authors.initials: YP
authors.lastname: Yao
authors.forename: Ruo-lei
authors.initials: RL
authors.lastname: Xin
authors.forename: Yun
authors.initials: Y
authors.lastname: Xu
authors.forename: Jie-zhe
authors.initials: JZ
authors.lastname: Yang
authors.forename: Zhi-hong
authors.initials: ZH
authors.lastname: Guo
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Pan
authors.forename: Jia-feng
authors.initials: JF
authors.lastname: Zhang
authors.forename: Ling-jie
authors.initials: LJ
authors.lastname: Liao
authors.forename: Hui
authors.initials: H
authors.lastname: Xing
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000494:pharmacology; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics*; D005260:Female; D005838:Genotype; D015497:HIV-1 / Q000145:classification / Q000187:drug effects* / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D019562:Viral Load; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents